GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » Cyclically Adjusted PB Ratio

Endonovo Therapeutics (Endonovo Therapeutics) Cyclically Adjusted PB Ratio : (As of Jun. 12, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Endonovo Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Endonovo Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics Cyclically Adjusted PB Ratio Chart

Endonovo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Endonovo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Endonovo Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Endonovo Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endonovo Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Cyclically Adjusted PB Ratio falls into.



Endonovo Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Endonovo Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Endonovo Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.076/129.4194*129.4194
=-0.076

Current CPI (Dec. 2023) = 129.4194.

Endonovo Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 -5,282.222 99.695 -6,857.169
201406 -967.773 100.560 -1,245.517
201409 -59.659 100.428 -76.881
201412 -57.639 99.070 -75.297
201503 -50.213 99.621 -65.233
201506 -54.746 100.684 -70.371
201509 -58.156 100.392 -74.972
201512 -88.511 99.792 -114.789
201603 -83.230 100.470 -107.211
201606 -61.493 101.688 -78.263
201609 -68.278 101.861 -86.751
201612 -63.734 101.863 -80.976
201703 -57.896 102.862 -72.844
201706 -37.490 103.349 -46.947
201709 -46.413 104.136 -57.682
201712 -30.131 104.011 -37.492
201803 -25.515 105.290 -31.362
201806 -25.587 106.317 -31.147
201809 -36.924 106.507 -44.867
201812 -26.428 105.998 -32.268
201903 -22.496 107.251 -27.146
201906 -22.239 108.070 -26.632
201909 -19.857 108.329 -23.723
201912 -17.242 108.420 -20.582
202003 -1.545 108.902 -1.836
202006 -0.980 108.767 -1.166
202009 -0.738 109.815 -0.870
202012 -0.586 109.897 -0.690
202103 -0.310 111.754 -0.359
202106 -0.280 114.631 -0.316
202109 -0.263 115.734 -0.294
202112 -0.212 117.630 -0.233
202203 -0.222 121.301 -0.237
202206 -0.127 125.017 -0.131
202209 -0.123 125.227 -0.127
202212 -0.151 125.222 -0.156
202303 -0.090 127.348 -0.091
202306 -0.080 128.729 -0.080
202309 -0.072 129.860 -0.072
202312 -0.076 129.419 -0.076

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Endonovo Therapeutics  (OTCPK:ENDV) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Endonovo Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Endonovo Therapeutics (Endonovo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
Executives
Alan Brian Collier director, 10 percent owner, officer: CEO 6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann 10 percent owner, officer: President 6320 CANOGA AVENUE, WOODLAND HILLS CA 91367

Endonovo Therapeutics (Endonovo Therapeutics) Headlines

From GuruFocus

Endonovo Names Ira Weisberg President to Guide Global Medical Expansion

By Value_Insider Value_Insider 11-30-2022

Endonovo Therapeutics Issues Corporate Update

By Value_Insider Value_Insider 11-07-2022

Endonovo Launches SofPulse� into the Veterans Administration

By sperokesalga sperokesalga 05-02-2023

New Details on Endonovo's Spin-Off of SofPulse, Inc.

By Stock market mentor Stock market mentor 01-19-2023